Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 128 full-time employees. The company went IPO on 2019-06-19. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The firm is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Follow-Up Questions
Stoke Therapeutics Inc의 CEO는 누구입니까?
Mr. Ian Smith은 2023부터 회사에 합류한 Stoke Therapeutics Inc의 Chief Executive Officer입니다.
STOK 주식의 가격 성능은 어떻습니까?
STOK의 현재 가격은 $25.34이며, 전 거래일에 decreased 0% 하였습니다.
Stoke Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Stoke Therapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Stoke Therapeutics Inc의 시가총액은 얼마입니까?
Stoke Therapeutics Inc의 현재 시가총액은 $1.3B입니다
Stoke Therapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 11명의 분석가가 Stoke Therapeutics Inc에 대한 분석 평가를 실시했으며, 이는 6명의 강력한 매수, 9명의 매수, 2명의 보유, 0명의 매도, 그리고 6명의 강력한 매도를 포함합니다
